ABSTRACT
Background Changes in lifestyle, finances and work status during COVID-19 lockdowns may have led to biopsychosocial changes in people with pre-existing vulnerabilities such as Major Depressive Disorders (MDD) and Multiple Sclerosis (MS).
Methods Data were collected as a part of the RADAR-CNS (Remote Assessment of Disease and Relapse – Central Nervous System) programme. We analyzed the following data from long-term participants in a decentralized multinational study: symptoms of depression, heart rate (HR) during the day and night; social activity; sedentary state, steps and physical activity of varying intensity. Linear mixed-effects regression analyses with repeated measures were fitted to assess the changes among three time periods (pre, during and post-lockdown) across the groups, adjusting for depression severity before the pandemic and gender.
Results Participants with MDD (N=255) and MS (N=214) were included in the analyses. Overall, depressive symptoms remained stable across the three periods in both groups. Lower mean HR and HR variation were observed between pre and during lockdown during the day for MDD and during the night for MS. HR variation during rest periods also decreased between pre-and post-lockdown in both clinical conditions. We observed a reduction of physical activity for MDD and MS upon the introduction of lockdowns. The group with MDD exhibited a net increase in social interaction via social network apps over the three periods.
Conclusions Behavioral response to the lockdown measured by social activity, physical activity and HR may reflect changes in stress in people with MDD and MS.
Competing Interest Statement
VAN and SV are employees of Janssen Research and Development LLC. PA is employed by the pharmaceutical company H. Lundbeck A/S. PS has received personal compensation for serving on scientific advisory boards, steering committees, and independent data monitoring committees or have received speaker honoraria for Biogen, Merck, Novartis, TEVA and Celgene/BMS. LL has received personal compensation for serving on scientific advisory boards, steering committees or speaker honoraria for Novartis, Merck, Roche, Almirall, Bristol Myers Squibb, Janssen Cilag MM has served in scientific advisory board for Sanofi, Novartis, Merck, and has received honoraria for lecturing from Biogen, Merck, Novartis, Roche, Genzyme, Bristol Myers Squibb AZ has received travel expenses for scientific meetings from Biogen Idec, Merck Serono, and Novartis, speaking honoraria from Eisai, and a study grant from Novartis.
Funding Statement
The RADARCNS project received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115902. This Joint Undertaking receives support from the European Union s Horizon 2020 research and innovation program and EFPIA (www.imi.europa.eu). This communication reflects the views of the RADAR-CNS consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. The funding body was involved in the design of the study, the collection or analysis of data, or the interpretation of data.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval has been obtained in London from the Camberwell St Giles Research Ethics Committee (REC reference: 17/LO/1154), in London from the CEIC Fundacio Sant Joan de Deu (CI: PIC12817) and in The Netherlands from the Medische Ethische Toetsingscommissie VUms (METc VUmc registratienummer: 2018.012 NL63557.029.17).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Patients advisory board.
Data Availability
All data produced in the present work are contained in the manuscript
Abbreviations
- COVID-19
- COronaVIrus Disease 19
- HR
- Heart rate
- MDD
- Major depressive disorder
- MS
- Multiple Sclerosis
- mHR
- mean HR
- PPG
- photoplethysmography
- PHQ-8
- 8-item Patient Health Questionnaire
- RADAR-CNS
- Remote assessment of disease and relapse - central nervous system
- RADAR-MDD
- Remote assessment of disease and relapse-major depressive disorder
- RMT
- Remote measurement technology
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- stdHR
- Standard deviation Heart Rate
- WHO
- World Health Organization
